Moxicin

Moxicin

moxifloxacin

Manufacturer:

Amarox
Concise Prescribing Info
Contents
Moxifloxacin
Indications/Uses
Acute exacerbation of chronic bronchitis. Community acquired pneumonia. Adequately diagnosed acute bacterial sinusitis. Complicated skin & skin structure infections. Complicated intra-abdominal infections. Mild to moderate pelvic inflammatory disease w/o associated tubo-ovarian or pelvic abscess in combination w/ appropriate antibacterial agent.
Dosage/Direction for Use
Recommended dose: 400 mg once daily. Duration of treatment: Acute exacerbation of chronic bronchitis 5-10 days. Community acquired pneumonia 10 days. Acute sinusitis 7 days. Complicated skin & skin structure infections 7-21 days (sequential IV/oral therapy). Complicated intra-abdominal infections 5-14 days (sequential IV/oral therapy). Mild to moderate pelvic inflammatory disease 14 days.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity to moxifloxacin or other quinolones. Patients w/ history of tendon disease/disorder related to quinolone treatment. Patients w/ congenital or documented acquired QT prolongation. Electrolyte disturbances eg, hypokalemia. Clinically relevant bradycardia; heart failure w/ reduced left-ventricular ejection fraction. Previous history of symptomatic arrhythmias. Concurrent use w/ other drugs that prolong QT interval eg, class IA & class III, antiarrhythmic agents. Patients w/ impaired liver function (Child Pugh C); increased transaminases >5 fold times the upper limit of normal; CrCl <30 mL/min/1.73 m2 (serum creatinine >265 mcmol/L) or undergoing renal dialysis. Pregnancy & lactation. Patients <18 yr.
Special Precautions
Patients w/ CNS disorders, myasthenia gravis, G6PD deficiency, galactose intolerance, Lapp-lactase deficiency or glucose-galactose malabsorption, visual impairment or any effect on the eyes, psychosis or history of psychiatric disease. Tendon inflammation & rupture may occur during therapy in elderly patients & those who have currently treated w/ corticosteroids. Discontinue treatment at 1st sign of pain or inflammation, cardiac arrhythmia, shock. Concomitant use w/ medication that reduce K & Mg levels. Perform liver function tests/investigations. Pseudomembranous colitis. Avoid exposure to either UV irradiation or extensive &/or strong sunlight during treatment. Patients for whom Na intake is of medical concern eg, CHF, renal failure, nephrotic syndrome. Increased risk for ventricular arrhythmias eg, Torsades de pointes. Cases of fulminant hepatitis that may lead to liver failure eg, fatal cases; bullous skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis, sensory or sensorimotor polyneuropathy that may result to paraesthesias, hypoaesthesias, dysaesthesias or weakness. Not recommended for the treatment of MRSA infections. May cause false negative Mycobacterium spp. culture test result. Monotherapy w/ moxifloxacin should be avoided in patients w/ pelvic inflammatory disease. Dysglycemia. Monitor carefully for blood glucose. Not recommended in patients w/ complicated pelvic inflammatory disease eg, associated w/ a tubo-ovarian or pelvic abscess for whom an IV treatment is necessary. May impair ability to drive or operate machinery due to CNS reactions eg, dizziness & vision disorders. Women. Elderly.
Adverse Reactions
Mycotic superinfections; headache, dizziness; QT prolongation in patients w/ hypokalemia; nausea, vomiting, GI & abdominal pains, diarrhea; increased transaminases; inj & infusion site reactions; increased γ-glutamyl-transferase.
Drug Interactions
Concomitant use w/ antacids eg, Mg or Al hydroxide, didanosine, sucralfate, minerals & multivit eg, Fe or Zn may impair absorption. Increased Cmax of Digoxin by approximately 30%. May decrease peak plasma conc of glibenclamide. Concurrent use w/ other drugs that prolong QT interval eg, anti-arrhythmics class IA eg, quinidine, hydroquinidine, disopyramide or anti-arrhythmics class III eg, amiodarone, sotalol, dofetilide, ibutilide, neuroleptics eg, phenothiazines, pimozide, sertindole, haloperidol, sultopride, TCAs, certain antimicrobials eg, sparfloxacin, erythromycin IV, bepridil, diphemanil may increase risk of ventricular arrhythmias notably Torsade de pointes. Drugs that induce bradycardia or hypokalemia or which induce QT prolongation eg, neuroleptic, certain anti-infective agents eg, some antimalarials, azole antimycotics, macrolides, certain antihistaminics eg, terfenadine, astemizole, cisapride. Increased anticoagulant activity w/ concurrent use of anticoagulants. Reduced systemic availability by >80% w/ charcoal.
MIMS Class
Quinolones
ATC Classification
J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Presentation/Packing
Form
Moxicin FC tab 400 mg
Packing/Price
1 × 5's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in